RB's OTC Sales Slump 9% In Q1 As Cold Season Fails To Materialize
Executive Summary
Reckitt Benckiser was hit badly by the weak cold and flu season in the US and Europe at the start of 2019, causing its OTC sales to drop by 9%. Despite supplement sales also struggling, the firm insists it will still hit its revenue targets for the full year, with growth expected in the second half.
You may also be interested in...
Reckitt Struggles To Tame Enlarged Health Portfolio As Durex and Scholl Stumble In Q2
Durex, Scholl and a number of regional OTC brands fell short of expectations in Q2 as RB reported like-for-like Health sales down by 1%. Analysts are now questioning whether the UK-based firm has expanded too fast and spread itself too thin in the global consumer health market as it struggles to get the most out of its diverse portfolio.
Reckitt Names New CEO To Ignite Growth And Lead Digital Transformation
Reckitt Benckiser has poached PepsiCo's global chief commercial officer, Laxman Narasimhan, to replace Rakesh Kapoor as the UK-based firm's CEO. Setting his stall out early, Narasimhan has made clear that RB's "capabilities and culture" need to change to make the company fit for the new digital world.
Reckitt ‘Not Happy’ With Consumer Health Growth In 2018, Following European And Infant Nutrition Woes
RB's Health business failed to keep pace with market growth in 2018, with the firm admitting its mindset in Europe "needs to change." The UK-based consumer-goods giant spent the 12 months working on its RB 2.0 restructuring program, which will give it the option to separate into two independent companies focusing on Health and Hygiene by 2020.